WisdomTree U.S. MidCap Quality Growth Fund (QMID) has seen unusual trading volume, which is 24× higher than its average daily volume.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Among QMID’s largest positions, Roivant Sciences has been in focus after Bernstein initiated coverage with an Outperform rating and a $35 price target, pointing to upside from upcoming clinical readouts, while investors also weighed a large insider sale by a senior executive and the positive impact of a $2.25B patent settlement and FDA Priority Review for brepocitinib. Permian Resources, another key holding, drew attention as JPMorgan raised its price target to $26 and reaffirmed an Overweight rating, citing tighter oil market fundamentals tied to Middle East conflict and the closure of the Strait of Hormuz, alongside recent upgrades to investment grade credit ratings and analyst optimism about its capital-efficient development plans and free cash flow profile.